Patient Selection and 30-Day Outcomes of SADI-S Compared to RYGB: a Retrospective Cohort Study of 47,375 Patients

Kevin Verhoeff1 · Valentin Mocanu1 · Uzair Jogiat1 · Hayley Forbes1 · Noah J. Switzer1 · Daniel W. Birch2 · Shahzeer Karmali2

Received: 30 January 2022 / Revised: 7 April 2022 / Accepted: 13 April 2022 / Published online: 21 April 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Purpose Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) offers a novel bariatric procedure with few comparative studies evaluating patient selection or perioperative outcomes. We aim to compare SADI-S to Roux-en-Y gastric bypass (RYGB).

Materials and Methods The 2020 Metabolic and Bariatric Accreditation and Quality Improvement Program (MBSAQIP) registry was analyzed, comparing SADI-S to RYGB. Bivariate analysis was performed to determine intergroup differences. Multivariable logistic regression determined factors associated with serious complications and mortality.

Results We evaluated 47,375 patients, with 501 (1.1%) receiving SADI-S. Patients undergoing SADI-S had higher body mass index (51.4 ± 9.7 kg/m² SADI-S vs. 44.6 ± 7.9 kg/m² RYGB; \( p < 0.001 \)), and more metabolic comorbidities including non-insulin dependent diabetes (21.7% SADI-S vs 19.0% RYGB; \( p = 0.011 \)), insulin dependent diabetes (12.0% SADI-S vs. 8.6% RYGB; \( p = 0.011 \)), and hypertension (54.9% SADI-S vs 47.6% RYGB; \( p < 0.001 \)). Patients undergoing SADI-S experienced more anastomotic leaks (2.2% vs. 0.5%; \( p < 0.001 \)), reoperations (5.0% vs 2.6%; \( p < 0.001 \)), pneumonias (1.6% vs 0.5%; \( p < 0.001 \)), had sepsis more frequently (1.4% vs 0.3%; \( p < 0.001 \)), and required more unplanned reintubations (1.2% vs 0.3%; \( p = 0.004 \)). SADI-S was independently associated with serious complications (\( OR \ 1.45, CI \ 1.09–1.95, p < 0.001 \)) but was not a predictor of mortality (\( OR \ 3.29, p = 0.060 \)).

Conclusions In comparison to RYGB, patients undergoing SADI-S were found to have more metabolic comorbidities. Compared to RYGB, SADI-S has worse perioperative outcomes and is independently associated with serious complications. It remains unclear whether this represents a learning curve or true findings and prospective studies analyzing the risk–benefit ratio following SADI-S are needed.

Key Points SADI-S is offered to younger patients with more metabolic comorbidities.

SADI-S may have increased perioperative risks compared to RYGB.

SADI-S may be independently associated with serious complications.

Future studies remain needed to completely characterize SADI-S outcomes.

Kevin Verhoeff
verhoeff@ualberta.ca

1 Department of Surgery, University of Alberta, Edmonton, AB, Canada

2 Centre for Advancement of Surgical Education and Simulation (CASES), Royal Alexandra Hospital, Edmonton, AB, Canada
Keywords  SADI-S · Bariatric surgery · Single anastomosis duodeno-ileal bypass with sleeve gastrectomy · Duodenal switch · RYGB

Introduction

Studies evaluating single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) have increased dramatically in the last decade. Initially described by Sanchez-Pernaute in 2007, SADI-S combines sleeve gastrectomy (SG) with a modified duodenal switch (DS) procedure using only one anastomosis [1]. Its description originated primarily due to concerns regarding substantial perioperative risk with the classic DS, despite recognized metabolic benefits. By completing only one anastomosis but achieving similar anatomy to a DS and adding a restrictive component, proponents suggest that SADI-S could achieve improved long-term metabolic outcomes to Roux-en-Y gastric bypass (RYGB) with similar or better perioperative outcomes [2]. Despite many studies reporting improved perioperative outcomes with SADI-S compared to DS [3–8], only one single-center retrospective cohort study has compared SADI-S to RYGB, the gold-standard metabolic procedure. To best evaluate the risk–benefit profile of SADI-S, studies investigating patient selection and perioperative outcomes compared to RYGB are needed.

The original statement on SADI-S from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) in 2018 considered potential benefits from SADI-S, but suggested ongoing evaluation due to limited studies [10]. Since then, several studies and two systematic reviews have evaluated SADI-S suggesting that perioperative risks for SADI-S are reduced compared to DS and demonstrating promising short and medium term outcomes [3–8]. In response, an updated statement from IFSO stated that SADI-S has substantial weight loss and comorbidity improvements, but suggested additional evidence evaluating perioperative outcomes, and long-term results [11].

We aimed to provide the largest study to date evaluating patient selection and perioperative outcomes for patients undergoing SADI-S compared to RYGB. Understanding which patients are being selected for SADI-S and comparing outcomes to RYGB, the current gold standard bariatric procedure, will enable better assessment of the utility of SADI-S for bariatric surgeons and will help guide future studies evaluating this relatively new technique.

Materials and Methods

Data Source

Data from the 2020 MBSAQIP database was evaluated for this study. This data is prospectively collected for patients undergoing bariatric surgery from 885 centers in North America and characterized key pre-operative, operative, and post-operative outcomes for nearly 1 million patients. Only MBSAQIP accredited centers contribute data and all participating centers are subject to frequent review of data collection practices to ensure accuracy and reliability. Data is collected based on well-defined, uniform variables and collected anonymously [12]. Due to data anonymity and the
source of data, this study was exempt from research ethics board review.

**Study Design, Patient Population, and Variable Definitions**

This is a retrospective cohort study of prospectively collected data. The primary outcomes of this study were to comparatively assess patient selection and 30-day perioperative outcomes for patients undergoing SADI-S compared to RYGB. Secondary outcomes evaluated the influence of SADI-S on serious postoperative complications and 30-day mortality among bariatric surgery patients.

Patients included in this study were categorized into two distinct cohorts, those undergoing SADI-S and those undergoing RYGB as categorized by the MBSAQIP. Patients receiving other procedures including sleeve gastrectomy, intragastric balloon, standard DS, and gastric band were excluded; this was done in order to directly compared SADI-S to the gold-standard bariatric surgery procedure. Only patients undergoing first-time elective bariatric surgery were included.

To assess patient selection, demographics were obtained and compared between both cohorts. Comparisons were made evaluating gender, race, and pre-operative body mass index (BMI). Cardiac comorbidities evaluated were hyperlipidemia, hypertension, previous myocardial infarction (MI), previous percutaneous coronary intervention (PCI), and previous cardiac surgery. Pulmonary comorbidities evaluated were presence of active smoking, sleep apnea, and chronic obstructive pulmonary disease (COPD). Other comorbidities evaluated to characterize patient selection were history of venous thromboembolism (VTE), gastroesophageal reflux disease (GERD), diabetes mellitus (DM), venous stasis, renal insufficiency, dialysis dependency, therapeutic anticoagulation, and chronic steroid use. Operative time was also assessed to comparatively assess procedure time of both techniques.

Perioperative outcomes evaluated 30-day readmission to hospital, reoperation, and reintervention based on MBSAQIP definitions [12]. Additionally, infectious complications such as the rate of anastomotic leak, deep surgical site infection (SSI), wound disruption, urinary tract infection (UTI), pneumonia, and sepsis are reported. Other post-operative complications evaluated include unplanned intubation, acute renal failure (described as any renal failure requiring dialysis), myocardial infarction (MI), and cerebral vascular accidents (CVA). We also evaluated emergency department re-presentation and the need for outpatient dehydration treatment. Furthermore, we evaluated mortality, and serious complications, post-operative bleeding, and anastomotic leak as defined in the appendix.

**Statistics Analysis**

In all cases, categorical data was expressed as absolute values with percentages, while continuous data were expressed as a weighted mean ± standard deviation. Cohort differences were evaluated using chi-squared for categorical data and ANOVA for continuous data. All statistical analysis was completed using the STATA 17 statistical software (StataCorp, College Station, TX, USA).

To adjust for comorbidities and determine independent predictors of 30-day post-operative serious complications and mortality, a non-parsimonious multivariable logistic regression model was developed using a hypothesis-driven purposeful selection methodology. Bivariate analysis of variables with a *p*-value <0.1 or from variables previously deemed clinically relevant to our primary outcome were used to generate a main effects model. The Brier Score (BS) and the receiver operating characteristic (ROC) curve were used to assess goodness of fit.

**Results**

**Patient Demographics**

A total 47,375 were included in this study, with 501 (1.1%) undergoing SADI-S. Patients selected for SADI-S were younger (43.2 ± 11.6 SADI-S vs. 45.4 ± 11.5 RYGB; *p* < 0.001) and were more likely to be female (76.3% SADI-S vs 74.8% RYGB; *p* < 0.001). Patients undergoing SADI-S also had a significantly higher BMI (51.4 ± 9.7 kg/m² SADI-S vs. 44.6 ± 7.9 kg/m² RYGB; *p* < 0.001) and a higher ASA classification, with over twice as many being ASA class 4-5 (9.8% SADI-S vs 4.1% RYGB; *p* < 0.001; Table 1). Additionally, patients receiving SADI-S had more metabolic comorbidities including non-insulin dependent diabetes (21.7% SADI-S vs 19.0% RYGB; *p* = 0.011), insulin dependent diabetes (12.0% SADI-S vs 8.6% RYGB; *p* = 0.011), hypertension (54.9% SADI-S vs 47.6% RYGB; *p* < 0.001), and had more hyperlipidemia, although this difference was not statistically significant (29.5% SADI-S vs 26.1% RYGB; *p* = 0.081). Otherwise, SADI-S and RYGB patients were similar with regards to other comorbidities (Table 1).

**Bivariate Analysis of Post-Operative Outcomes**

Patients undergoing SADI-S were more likely to experience anastomotic leak (2.2% vs. 0.5%; *p* < 0.001) and required reoperation twice as frequently (5.0% vs 2.6%; *p* < 0.001; Table 2). Other key perioperative differences between groups included that patients undergoing SADI-S experienced sepsis more frequently (1.4% vs 0.3%; *p* < 0.001),...
required unplanned reintubation (1.2% vs 0.3%; \( p = 0.004 \)), and had more acute renal failure (1.0% vs 0.2%; \( p < 0.001 \)), and pneumonia (1.6% vs 0.5%; \( p < 0.001 \)). Patients undergoing RYGB required more outpatient dehydration treatment (4.1% vs 3.8%; \( p = 0.034 \)); however, emergency department re-presentation was similar between groups (9.5% vs 13.2%; \( p = 0.987 \)). Most notably, patients undergoing SADI-S had significantly increased mortality (0.6% vs 0.1%; \( p = 0.004 \)). Serious complications were higher after SADI-S but differences were not statistically significant (10.6% vs 8.3%; \( p = 0.070 \)), and other complications were similar between groups (Table 2).

### Multivariable Logistic Regression Evaluating Predictors of Serious Complications and Mortality

On multivariable analysis, renal insufficiency and prior MI were the most substantial contributors to serious

### Table 1

| Patient characteristics | SADI-S \( n = 501 \) | RYGB \( n = 46,874 \) | \( p \)-value* |
|-------------------------|----------------------|----------------------|----------------|
| Age, years | Mean ± SD | 43.2 ± 11.6 | 45.4 ± 11.5 | < 0.001 |
| Gender | | | | < 0.001 |
| Female | | 382 (76.3) | 129,429 (74.8) | |
| Male | | 119 (23.8) | 7593 (16.2) | |
| BMI, kg/m² | Mean ± SD | 51.4 ± 9.7 | 44.6 ± 7.9 | < 0.001 |
| ASA class | | | | |
| 1–2 | | 46 (9.2) | 7841 (16.7) | < 0.001 |
| 3 | | 405 (80.8) | 37,060 (79.1) | |
| 4–5 | | 49 (9.8) | 1922 (4.1) | |
| Smoker | | | | 0.010 |
| Diabetes | | | | |
| No or diet controlled | | 332 (66.3) | 125,419 (72.5) | 0.111 |
| Non-insulin dependent | | 109 (21.7) | 32,864 (19.0) | |
| Insulin dependent | | 60 (12.0) | 14,827 (8.6) | |
| Hypertension | | 275 (54.9) | 22,293 (47.6) | 0.001 |
| GERD | | 123 (24.6) | 21,461 (45.8) | < 0.001 |
| COPD | | 10 (2.0) | 690 (1.5) | 0.334 |
| Hyperlipidemia | | 148 (29.5) | 12,231 (26.1) | 0.081 |
| Chronic steroid use | | 15 (3.0) | 1018 (2.2) | 0.210 |
| Renal insufficiency | | 2 (0.4) | 264 (0.6) | 0.625 |
| Dialysis dependent | | 1 (0.2) | 96 (0.2) | 0.980 |
| History of DVT | | 12 (2.4) | 1033 (2.2) | 0.772 |
| Venous stasis | | 4 (0.8) | 368 (0.8) | 0.973 |
| Preoperative therapeutic anticoagulation | | 18 (3.6) | 1467 (3.1) | 0.554 |
| Sleep apnea | | 222 (44.3) | 19,274 (41.1) | 0.149 |
| History of MI | | 5 (1.0) | 553 (1.2) | 0.708 |
| Previous major cardiac surgery | | 5 (1.0) | 429 (0.9) | 0.847 |
| Previous PCI | | 2 (0.4) | 784 (1.7) | 0.066 |
| Conversion to Open | | 0 (0) | 10 (0.2) | 0.923 |
| Operative time, minutes | Mean ± SD | 142.1 ± 60.3 | 131.2 ± 63.2 | < 0.001 |

SADI-S, single anastomosis duodeno-ileal bypass with sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; SD, standard deviation; BMI, body mass index; ASA, American Society of Anesthesiologists; GERD, gastroesophageal reflux disease; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; MI, myocardial infarction; PCI, percutaneous coronary intervention

*p-values were determined using chi-squared analysis for categorical data and ANOVA for continuous data
### Table 2
Thirty-day post-operative outcomes for patients undergoing single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) to those undergoing Roux-en-Y gastric bypass (RYGB)

| Risk factor                        | SADI-S n = 501 | RYGB n = 46,874 | p-value |
|------------------------------------|----------------|-----------------|---------|
| Anastomotic leak                   | 11 (2.2)       | 215 (0.5)       | <0.001  |
| Gastrointestinal bleed             | 7 (1.4)        | 352 (0.8)       | 0.407   |
| Readmission                        | 38 (7.6)       | 2703 (5.8)      | 0.083   |
| Reintervention                     | 14 (2.8)       | 901 (1.9)       | 0.158   |
| Reoperation                        | 25 (5.0)       | 1221 (2.6)      | <0.001  |
| Urinary tract infection            | 1 (0.2)        | 223 (0.5)       | 0.669   |
| Deep SSI                           | 2 (0.4)        | 79 (0.2)        | 0.448   |
| Sepsis                             | 7 (1.4)        | 121 (0.3)       | <0.001  |
| Wound disruption                    | 0 (0)          | 46 (0.1)        | 0.774   |
| Unplanned intubation               | 6 (1.2)        | 146 (0.3)       | 0.004   |
| Acute renal failure                | 5 (1.0)        | 82 (0.2)        | <0.001  |
| Pneumonia                          | 8 (1.6)        | 214 (0.5)       | <0.001  |
| Myocardial infarction              | 1 (0.2)        | 14 (0.03)       | 0.034   |
| Outpatient dehydration treatment   | 19 (3.8)       | 1925 (4.1)      | 0.031   |
| Emergency re-presentation          | 4 (9.5)        | 641 (13.2)      | 0.987   |
| Cerebral vascular accidents        | 0 (0)          | 16 (0.03)       | 0.679   |
| Serious complications              | 53 (10.6)      | 3905 (8.3)      | 0.070   |
| Mortality                          | 3 (0.6)        | 60 (0.1)        | 0.004   |

**SADI-S**, single anastomosis duodeno-ileal bypass with sleeve gastrectomy; **RYGB**, Roux-en-Y gastric bypass; **SSI**, surgical site infection.

complications followed closely by SADI-S procedure (OR 1.45, CI 1.09–1.95, p < 0.001 Table 3). Other factors independently associated with serious complications included GERD, COPD, prior DVT, and smoking history. On the other hand, increased age and BMI, and male gender, appeared to be protective (Table 3). The multivariable model predicted serious complications accurately with an area under the curve of 0.8847 and Brier score of 0.0012.

The most substantial factors associated with mortality were complications including anastomotic leak (OR 20.65, p < 0.001) and postoperative bleed (OR 9.90, p < 0.001), followed by renal insufficiency (OR 7.21, p < 0.001). Other independent factors statistically associated with mortality were previous MI, increased age, and BMI (Table 4). SADI-S had higher odds of mortality, although the effect was not statistically significant (OR 3.29, p = 0.060). This multivariable model for mortality had an area under the curve of 0.6029 and Brier score of 0.0755.

### Discussion

This is the largest study to date comparatively evaluating patient selection and perioperative outcomes following SADI-S. Although patients undergoing SADI-S were younger, they had increased BMI and greater metabolic comorbidities than patients receiving RYGB. SADI-S resulted in worse perioperative outcomes, including a significant increase in anastomotic leak, reoperation, sepsis, unplanned reintubation, acute renal failure, pneumonia, and mortality. After adjusting for comorbidities, SADI-S remained a substantial independent contributor to 30-day serious complications. Overall, patients selected for SADI-S appears to be more comorbid, while perioperative outcomes should be evaluated with caution and require further investigation to determine the effect of SADI-S learning curves and center experience.

Previous studies evaluating SADI-S have shown similar findings for patient selection. Both current systematic reviews evaluating SADI-S, one evaluating observational studies and the other comparative studies, both found that patients undergoing SADI-S had increased rates of DM and higher BMI compared to other procedures including RYGB [9, 13, 14]. Studies comparing demographics specifically between patients receiving SADI-S and RYGB have had similar findings [15, 16]. Because DS procedures were previously reported to be highly effective in terms of metabolic comorbidity reversal, and that SADI-S has been purported as a safer surgical option with similar benefits, these patient selection findings make sense [9, 17]. Early and medium term outcomes following SADI-S have also
Obesity Surgery (2022) 32:2116–2123

The results from our study contradict previous studies and found similar perioperative outcomes between groups. Surve et al. (2021), who evaluated a matched cohort of 61 patients undergoing SADI-S and RYGB from a single site and found similar perioperative outcomes between groups [2]. The results from our study contradict previous studies and introduces potential concerns regarding the perioperative risk associated with SADI-S, especially considering its independent association with serious complications. Notably, however, it should be highlighted that MBSAQIP outcomes represent procedures completed at 885 centers, including those who are adept at SADI-S and those who are just beginning its use. Our data suggest a nearly double rate of mortality, reoperation, and complication compared to the recent systematic review by Verhoeff et al. (2022) and therefore, results should be interpreted cautiously [9]. SADI-S represents a relatively new technique and complications found in this study may represent a learning curve as it is introduced more broadly. Furthermore, the definition of serious complications represents a composite variable including several outcomes and may explain some of the differences in outcomes found in this study. Comparative evaluation of outcomes over time may be beneficial. Furthermore, the metabolic benefits for high risk patients that appear to be selected for SADI-S may also outweigh these risks in certain circumstances.

To summarize, it appears that patients selected for SADI-S appear to have more comorbidities, which most studies have found. On the other hand, while experienced centers have found promising outcomes following SADI-S, this study suggests higher complications. While results from this study may represent findings due to a learning curve and should be considered, they do not necessarily preclude use of SADI-S. They do however highlight that a patient-by-patient risk–benefit assessment is required. For example, SADI-S may offer a potential treatment option for patients suffering from super-obesity, which represent a growing population that are often difficult to treat, especially with regards to long-term metabolic outcomes [20–25]. In these patients, the benefits of rapid metabolic improvements potentially achieved with SADI-S may prove to be life-saving. Additionally, offering SADI-S as a revisional procedure following SG, or as a two stage procedure, may reduce perioperative complications and maintain metabolic benefits [26–36]. Ongoing studies evaluating implementation of SADI-S, long term outcomes, and data evaluating the learning curve of this procedure would greatly benefit surgeons as they attempt to best serve a variety of patients.

This study has a number of limitations, most substantial of which is that this study is retrospective in nature and limited by data collected by the MBSAQIP. Applying a retrospective analysis may introduce important selection or bias that should be recognized. Data collected during this study was collected during the COVID-19 pandemic, which may also affect patient selection or outcomes. Unfortunately, the MBSAQIP did not definitively characterize outcomes for patients undergoing SADI-S previously, preventing us from presenting a longitudinal analysis. However, the COVID-19 pandemic is likely to affect both groups equally and has recently been shown to not affect perioperative outcomes substantially in bariatric surgery patients [37]. Furthermore, this study only evaluates primary, single stage SADI-S procedures, and the outcomes, risks, and potential benefits may differ in scenarios where SADI-S is applied as a revisional

| Table 4 Multivariable logistic regression for 30-day mortality |
|---------------------------------|-----------------|-----------------|-----------------|
| Risk factor                     | Odds ratio      | 95% confidence interval | p-value |
| SADI-S (as compared to RYGB)    | 3.29            | 0.95–11.34       | 0.060     |
| Age (compared by decade)        | 2.37            | 1.77–3.18        | < 0.001   |
| Male gender                     | 1.78            | 0.97–3.27        | 0.061     |
| BMI                             | 1.46            | 1.26–1.69        | < 0.001   |
| Renal insufficiency             | 7.21            | 2.91–17.87       | < 0.001   |
| Dialysis dependence             |                 |                  |           |
| Previous MI                     | 2.74            | 1.05–7.17        | 0.040     |
| GERD                            | 1.73            | 0.98–3.05        | 0.057     |
| Hypertension                    | 1.49            | 0.73–3.03        | 0.278     |
| Hyperlipidemia                  | 1.08            | 0.58–2.00        | 0.802     |
| Diabetes (as compared to no diabetes) | 0.75          | 0.36–1.58        | 0.456     |
| Non-insulin dependent Insulin dependent | 0.97         | 0.45–2.08        | 0.941     |
| COPD                            | 0.19            | 0.02–1.49        | 0.113     |
| Smoker                          | 1.24            | 0.46–3.35        | 0.670     |
| Anticoagulation                 | 1.34            | 0.56–3.20        | 0.512     |
| Operative duration              | 1.00            | 1.00–1.00        | 0.027     |
| Anastomotic leak                | 20.65           | 9.44–45.19       | < 0.001   |
| Postoperative bleed             | 9.90            | 4.69–20.90       | < 0.001   |
| Prior DVT                       | 2.50            | 0.91–6.90        | 0.077     |

SADI-S, single anastomosis duodeno-ileal bypass with sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; BMI, body mass index; MI, myocardial infarction; GERD, gastroesophageal reflux disease; COPD, chronic obstructive pulmonary disease; DVT, Deep Vein Thrombosis
procedure or two stage procedure, both of which have been described [26–36, 38]. The MBSSQIP also collects data from 885 centers, which although offers the strength of large sample sizes, fails to characterize outcomes from specific centers. As discussed, outcomes presented here represent those from North American centers as a whole, including those who are just beginning SADI-S, and those who are proficient; this may account for higher complication rates found in this study compared to those reported by single centers with large SADI-S volumes. Similarly, this data represents only an average of patient selection and outcomes for those 885 centers, and outcomes or patient selection may vary among those centers. Finally, the MBSSQIP does not capture long-term outcomes, limiting our evaluation of the potential metabolic benefits offered by SADI-S.

Despite limitations, this is the largest study comparatively evaluating patient selection and perioperative outcomes for patients undergoing SADI-S compared to RYGB. While patients selected for SADI-S appear to be more comorbid, this study should help inform surgeons with regard to perioperative outcomes following SADI-S. Prospective studies evaluating long-term outcomes, novel approaches to SADI-S such as the two-stage procedure, and the potential for a learning curve with improved outcomes in the future are needed.

Conclusion

Current evidence, including findings from this study, suggest that SADI-S is being utilized in patients with greater BMI and metabolic comorbidities. While previous studies have suggested relative perioperative safety with SADI-S, findings here suggest significantly worse perioperative outcomes including a significant increase in anastomotic leak, reoperation, sepsis, unplanned reintubation, acute renal failure, pneumonia, and mortality. Additionally, after adjusting for comorbidities, SADI-S was independently associated with serious complications at 30-days. These findings need to be considered during the surgical risk assessment for potential patients. High quality prospective studies evaluating the balance of risks and benefits are needed prior to widespread uptake of this initially promising technique.

Appendix

Data Collection Definitions

Anastomotic leak — Defined by any of the following: reoperation for anastomotic/staple line leak, readmission for anastomotic/staple line leak, reintervention for anastomotic/staple line leak, drain present 30 days postoperatively, or death caused by anastomotic/staple line leak.

Postoperative bleed — Defined by any of the following: reoperation for bleed, readmission for bleed, reintervention for bleed, transfusion required in first 72 h of surgery start time, and death caused by bleeding.

Serious complication — Defined by any of the following: cardiac complications, pneumonia, acute renal failure, reoperation, reintervention, venous thromboembolism, deep surgical site infection, wound disruption, sepsis, unplanned intubation, leak, bleed, coma ≥ 24 h, and cerebral vascular accident.

Declarations

Ethics Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to Participate Informed consent does not apply for this study.

Conflict of Interest The authors declare no competing interests.

References

1. Sánchez-Pernaute A, Rubio Herrera MA, Pérez-Aguirre E, García Pérez JC, Cabrerizo L, Diez Valladares L, et al. Proximal duodenal–ileal end-to-side bypass with sleeve gastrectomy: proposed technique. Obesity Surgery. 2007;17(12):1614–8.
2. Surve A, Cottam D, Richards C, Medlin W, Belnap L. A matched cohort comparison of long-term outcomes of Roux-en-Y gastric bypass (RYGB) versus single-anastomosis duodeno-ileostomy with sleeve gastrectomy (SADI-S). Obesity Surgery. 2020.
3. Andalib A, Bouchard P, Alamri H, Bougie A, Demyttenaere S, Court O. Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S): short-term outcomes from a prospective cohort study. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2021;17(2):414–24.
4. Finno P, Osorio J, Garcia-Ruiz-de-Gordejuela A, Casajona A, Sorribas M, Admella V, et al. Single versus double-anastomosis duodenal switch: single-site comparative cohort study in 440 consecutive patients. Obes Surg. 2020;30(9):3309–16.
5. Moon RC, Kirkpatrick V, Gaskins L, Teixeira AF, Jawad MA. Safety and effectiveness of single- versus double-anastomosis duodenal switch at a single institution. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2019;15(2):245–52.
6. Pereira AM, Guimaraes M, Pereira SS, Ferreira de Almeida R, Monteiro MP, Nora M. Single and dual anastomosis duodenal switch for obesity treatment: a single-center experience. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2021;17(1):12–9.
7. Sessa L, Guidone C, Gallucci P, Capristo E, Mingrone G, Rafaeli L. Effect of single anastomosis duodenal-ileal bypass with sleeve gastrectomy on glucose tolerance test: comparison with other bariatric procedures. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2019;15(7):1091–7.
8. Surve A, Cottam D, Belnap L, Richards C, Medlin W. Long-Term (> 6 Years) Outcomes of duodenal switch (DS)
24. Versus single-anastomosis duodeno-ileostomy with sleeve gastrectomy (SADI-S): a matched cohort study. Obes Surg. 2021 Dec;31(12):5117–26. PubMed PMID: 34523085. Epub 2021/09/16. eng.

9. Verhoeft K, Kocanu V, Zalasky A, Dang J, Kung JY, Switzer NJ et al. Evaluation of metabolic outcomes following SADI-S: a systematic review and meta-analysis. Obesity Surgery. 2022 02/01/10.

10. Brown WA, Ooi G, Higa K, Himpens J, Torres A, Sadi-S/Oads ifAtfirlro. Single anastomosis duodenal-ileal bypass with sleeve gastrectomy/one anastomosis duodenal switch (SADI-S/OADS) IFSO position statement. Obesity surgery. 2018;28(5):1207–16.

11. Brown WA, de Leon Ballesteros GP, Ooi G, Higa K, Himpens J, Torres A, et al. Single anastomosis duodenal-ileal bypass with sleeve gastrectomy/one anastomosis duodenal switch (SADI-S/OADS) IFSO position statement-update 2020. Obes Surg. 2021;31(1):3–25.

12. American College of Surgeons. MBSAQIP participant use data file (PUD). American College of Surgeons; 2019 [cited 2019 September 14]; Available from: https://www.facs.org/quality-programs/mbsaqip/participant-use.

13. Shoar S, Poliaklin I, Rubenstein R, Saber AA. Single Anastomosis duodeno-ileal switch (SADIS): a systematic review of efficacy and safety. Obes Surg. 2018;28(1):104–13.

14. Spinios D, Skarentzos K, Esargian SM, Seymour KA, Economonopolus KP. The effectiveness of single-anastomosis duodenal ileal bypass with sleeve gastrectomy/one anastomosis duodenal switch (SADI-S/OADS): an updated systematic review. Obesity surgery. 2021.

15. Enochs P, Bull I, Surve A, Cottam D, Bovard S, Bruce J, et al. Comparative analysis of the single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) to established bariatric procedures: an assessment of 2-year postoperative data illustrating weight loss, type 2 diabetes, and nutritional status in a single US center. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2020;16(1):24–33.

16. Torres A, Rubio MA, Ramos-Levi AM, Sanchez-Pernaute A. Cardiovascular risk factors after single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S): a new effective therapeutic approach? Curr Atheroscler Rep. 2017;19(12):58.

17. Bordan NS, Yashkov YI. Evolution of biliopancreatic diversion in the treatment of morbid obesity and type 2 diabetes mellitus. Diabetes mellitus. 2017;20(3):201–9. Russian.

18. Surve A, Cottam D, Medlin W, Richards C, Belnap L, Horsley B, et al. Long-term outcomes of single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2020;16(1):1638–46.

19. Surve A, Rao R, Cottam D, Rao A, Ide L, Cottam S, et al. Early outcomes of primary SADI-S: an Australian experience. Obes Surg. 2020;30(4):1429–36.

20. Finkelstein EA, Khavjou OA, Thompson H, Trogdon J, Pan L. Obesity and severe obesity forecasts through 2030. American Journal of Preventive Medicine. 2012 06/01/12(6):563–70.

21. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. International journal of obesity (2005). 2013;37(6):889–91. PubMed PMID: 22986681. eng.

22. Ward JJ, Bleich SN, Braden AL, Barrett JL, Gils CM, Flax C, et al. Projected US state-level prevalence of adult obesity and severe obesity, New England Journal of Medicine. 2019 12/19/19;381(25):2440–50.

23. Verhoeft K, Kocanu V, Dang J, Purich K, Switzer NJ, Birch DW et al. Five years of MBSAQIP data: characteristics, outcomes, and trends for patients with super-obesity. Obes Surg. 2021 Nov 15. PubMed PMID: 34782985. Epub 2021/11/17. eng.

24. DeMaria EJ, Carmody BJ. Perioperative management of special populations: obesity. Surg Clin North Am. 2005;85(6):1283–9.

25. DeMaria EJ, Schauer P, Patterson E, Nguyen NT, Jacob BP, Inabnet WB et al. The optimal surgical management of the super-obese patient: the debate. Presented at the annual meeting of the Society of American Gastrointestinal and Endoscopic Surgeons, Hollywood, Florida, USA, April 13–16, 2005. Surg Innov. 2005 Jun;12(2):107–21. PubMed PMID: 16034493. Epub 2005/07/22. eng.

26. Balibrea JM, Vilallonga R, Hidalgo M, Ciudin A, Gonzalez O, Caubet E, et al. Mid-term results and responsiveness predictors after two-step single-anastomosis duodeno-ileal bypass with sleeve gastrectomy. Obes Surg. 2017;27(5):1302–8.

27. Ansari R, Lakadawala M, Sleeve to Sadi. Obesity surgery. 2018 Sep;28:107-. PubMed PMID: WOS:000445203700007.

28. Almalki OM, Lee WJ, Chen JC, Ser KH, Lee YC, Chen SC. Regional gastric bypass for failed restrictive procedures: comparison of single-anastomosis (Mini-) and Roux-en-Y gastric bypass. Obes Surg. 2018;28(4):970–5.

29. Bashshah M, Aleter A, Baazouji J, El-Menay A, Torres A, Salama A. Single anastomosis duodenal-ileostomy (SADI-S) versus one anastomosis gastric bypass (OAGB-MGB) as revisional procedures for patients with weight recidivism after sleeve gastrectomy: a comparative analysis of efficacy and outcomes. Obes Surg. 2020;30(12):4715–23.

30. Ceha CM, van Wezenbeek MR, Versteegden DPA, Smulders JF, Nienhuijs SW. Matched short-term results of SADI versus GBP after sleeve gastrectomy. Obes Surg. 2018;28(12):3809–14.

31. Conde M, Cerdan C, Sanchez-Pernaute A, Cabrerozo L, Talerreta P, et al. 2011 Single anastomosis duodeno-ileal bypass (SADI) vs classical duodenal switch as a second step after sleeve gastrectomy in morbid obese patients with initial BMI>50KG/M2. Obesity Surgery. 21(8):1010–1, English.

32. de la Cruz M, Busing M, Dukovskva R, Torres AJ, Reiser M. Short- to medium-term results of single-anastomosis duodenal ileal bypass compared with one-anastomosis gastric bypass for weight recidivism after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2020;16(8):1060–6.

33. Heneghan HM, Kerrigan DD. Laparoscopic SADI-S as a salvage procedure for failed gastric bypass and sleeve gastrectomy: how I do it. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2018;14(5):715–8.

34. Jawad MA, Nelson L, Moon RC, Teixeira AF. Techniques of single-stage laparoscopic conversion of Roux-en-Y gastric bypass to single anastomosis biliopancreatic diversion with duodenal switch. Obes Surg. 2017;27(4):1109–11.

35. Karucz WK, Kuesters S, Grueneberger J. Duodenal switch as malabsorptive revisionary option after conventional and banded gastric bypass. Obes Surg. 2012;22(9):1370–8 (English).

36. Moon RC, Alkhairi L, Wier AJ, Teixeira AF, Jawad MA. Conversions of Roux-en-Y gastric bypass to duodenal switch (SADI-S and BPD-DS) for weight regain. Surg Endosc. 2020;34(10):4422–8.

37. Verhoeft K, Kocanu V, Wilson H, Switzer N, Birch D, Karmali S. The effectiveness of single-anastomosis duodeno ileal bypass (SADI-S): a matched cohort study. Obes Surg. 2021 Dec;31(12):5117–26. PubMed PMID: 34523085. Epub 2021/09/16. eng.

Publisher’s Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.